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Background and aims: So far, no randomized trial or meta-analysis has been conducted on 
overall survival (OS) and recurrence-free survival (RFS) factors in patients treated with radiof-
requency ablation (RFA) alone. The purpose of this meta-analysis was to evaluate prognostic 
factors of OS and RFS in patients treated with RFA.
Methods: A primary analysis was planned to evaluate the clinical prognostic factor of OS. 
RFS was the secondary aim. Thirty-four studies published from 2003 to 2017 were analyzed. 
They included 11,216 hepatocellular carcinoma patients.
Results: The results showed that Child–Pugh B vs Child–Pugh A (HR =2.32; 95% CI: 
2.201–2.69; P,0.0001) and albumin–bilirubin score 1 vs 0 (HR =2.69; 95% CI: 2.10–3.44; 
P,0.0001) were predictive of poor OS. Tumor size as a continuous variable was not predic-
tive of OS, although it was predictive of OS when we considered the size as a cutoff value 
(.2 cm vs ,2 cm: HR =1.41; 95% CI: 1.23–1.61; P,0.0001; .3 cm vs ,3 cm: HR =1.43; 
95% CI: 1.17–1.74; P,0.0001) and in presence of .1 nodule (HR =1.59; 95% CI: 1.46–1.74; 
P,0.0001). Alpha-fetoprotein .20 ng/mL (HR =1.46; 95% CI: 1.25–1.70; P,0.0001) was 
the only predictive factor of poor prognosis.
Conclusion: Our meta-analysis highlighted that the maximum benefit of RFA in terms of OS 
and RFS is reached in the presence of Child–Pugh A, albumin–bilirubin score 1, single-nodule 
tumor sized ,2 cm, and alpha-fetoprotein ,20 ng/mL.
Keywords: radiofrequency, ALBI score, NLR, outcome, marker , immune-inflammation index, 
neutrophil-to-lymphocyte ratio, platelet-lymphocyte ratio, chil-pugh, alpha-fetoprotein
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide.1 
Hepatic resection and transplantation are considered the best treatments for early-stage 
patients with high probability of long-term survival.2 Radiofrequency ablation (RFA) is 
emerging as an effective local treatment for curative intent in patients with small HCC 
with a diameter ,3 cm.3,4 Several meta-analyses5,6 have shown that RFA and surgical 
resection have a comparable impact on overall (OS) and recurrence-free survival (RFS). 
Given the different therapeutic options that occur in patients with HCC in the initial stage, 
it is absolutely essential to identify prognostic factors that can predict the possibility of 
relapse. There are several works published by RFA. All these studies have a heterogeneous 
duration of patient groups, to tell the reason, it is difficult to compare them. Furthermore, 
to date, neither randomized studies on RFA vs best supportive care nor meta-analyses 
evaluating OS and RFS have been completed on RFA patients alone.
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The purpose of this meta-analysis was to evaluate prog-
nostic factors of OS and RFS in patients treated with RFA, 
with the aim to identify parameters that can help clinicians 
in the therapeutic choice, and determine stratification factors 
for future studies in this subset of patients.
Materials and methods
study design and inclusion criteria
Clinical trials on the prognostic factors of RFA in HCC 
patients were considered, excluding randomized controlled 
trials comparing RFA and surgery, studies with insufficient 
data to estimate the outcomes, and studies on RFA with 
microwave and ethanol. A primary analysis was planned to 
evaluate the clinical prognostic factor of OS. RFS was the 
secondary aim. OS was defined as the time interval between 
the day of start of treatment until the day of death or last 
follow-up visit. The RFS was defined as the observation 
time during the follow-up period during which the patient 
developed a intrahepatic distant recurrence, extrahepatic 
recurrence, or death.
search strategy
We conducted a bibliographic search of the PubMed, Embase, 
Cochrane Library. Keywords used included “radiofrequency 
AND hepatocellular carcinoma”, “radiofrequency AND liver 
cancer”. Articles published in English until September 2017 
and reporting data of studies conducted on human participants 
were retrieved. Relevant reviews and meta-analyses of loco-
regional treatments of unresectable HCC were also exam-
ined for potential suitable studies and data. The 2000–2017 
proceedings of the Annual Meeting of the American Society 
of Clinical Oncology (ASCO and ASCO Gastrointerstinal), 
European Society of Clinical Oncology (ESMO and ESMO 
Gastrointerstinal), European Association for the Study of the 
Liver, American Association for the Study of Liver Diseases, 
and International Liver Cancer Association were systemati-
cally reviewed for relevant unpublished data.
The computer search was supplemented with a manual 
search of the primary studies referenced in all of the retrieved 
review articles. When the results of a study were reported 
in multiple subsequent analyses, only the most recent and 
complete version was considered.
Data extraction and management
Two review authors (ACG and MV) independently screened 
the titles of all the selected studies, and read the abstracts of 
potentially eligible papers. Whenever discrepancies in trial 
search or selection occurred between the 2 review authors, 
they were discussed with a third review author (FGF) to reach 
an agreement. All selected trials published as full-text articles 
in peer-reviewed journals were analyzed and classified 
using the Newcastle–Ottawa Quality Assessment Scale for 
Cohort Studies. ACG and MV independently performed the 
qualitative and quantitative analysis of the selected articles. 
Whenever discrepancies occurred, they were discussed with 
FGF to reach an agreement.
statistical analysis
All analyses were carried out using Stata version 15.0 (Stata 
Corporation, College Station, TX, USA). HR reported 
in each study was used as an outcome measure of the 
prognostic value. The summary estimates were generated 
using a fixed-effect model (Mantel–Haenszel method) or a 
random-effect model49 depending on the absence or presence 
of heterogeneity.
The inter-study heterogeneity was examined by the 
Cochran’s Q and I-squared statistic with an I-squared .50% 
representing significant heterogeneity.7
We assessed the potential of publication bias by visually 
inspecting the funnel plot symmetry and Egger’s test for 
asymmetry.8
Sensitivity analyses were conducted by excluding 1 study 
at a time and reanalyzing the remaining to test whether the 
results had changed substantially by any individual study. 
A value of P,0.05 was regarded as statistically significant 
for all statistical analyses. All tests were 2-sided.
Results
study selection and characteristics
Figure 1 reports the search strategy used in this meta-analysis. 
Thirty-four9–42 studies published between 2003 and 2017 
were analyzed. They included 11,216 HCC patients treated 
with RFA. The characteristics of the study are gathered in 
Table 1.
Overall survival
The analysis of liver functionality showed that Child–
Pugh B vs Child–Pugh A (HR =2.32; 95% CI: 2.201–2.69; 
P,0.0001) (Figure 2A), increase in bilirubin (HR =1.03; 95% 
CI: 1.01–1.04; P,0.0001) (Figure 2B), presence of Portosys-
temic collaterals (HR =1.54; 95% CI: 1.31–1.82; P,0.0001) 
(Figure 2C), and albumin-bilirubin (ALBI) score 1 vs 0 
(HR =2.69; 95% CI: 2.10–3.44; P,0.0001) (Figure 2D) 
were predictive of poor OS. Decrease in prothrombin activity 
(HR =0.97; 95% CI: 0.96–0.99; P,0.0001) (Figure 2E) 
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and increase in albumin (HR =0.90; 95% CI: 0.87–0.94; 
P,0.0001) (Figure 2F) were predictive of better OS.
Tumor size was not predictive of OS (HR =1.01; 95% 
CI: 0.99–1.03; P=0.269) (Figure 3A) when considered as 
a continuous variable. Yet, it was predictive of OS when 
considered as a cutoff value. An either size cutoff of 2 or 
3 cm was predictive of poor OS (.2 cm, HR =1.41; 95% CI: 
1.23–1.61; P,0.0001, Figure 3B; .3 cm, HR =1.43; 95% 
CI: 1.17–1.74; P,0.0001, Figure 3C). When considering the 
number of nodules, the presence of .1 nodules (HR =1.59; 
95% CI: 1.46–1.74; P,0.0001) (Figure 3D) was predictive 
of poor OS. 
Gender was not predictive of OS (male vs female 
HR =1.07; 95% CI: 0.99–1.15; P=0.091) (Figure S1A), while 
an older age (HR =1.02; 95% CI: 1.01–1.03; P,0.0001) 
(Figure S1B) and an age .65 years (HR =1.73; 95% CI: 
1.40–2.12; P,0.0001) (Figure S1C) were predictive of 
poor OS.
Data showed that an alpha-fetoprotein cutoff of 20 ng/mL 
(.20 ng/mL vs ,20 ng/mL HR =1.46; 95% CI: 1.25–1.70; 
P,0.0001) (Figure 4A) was predictive of poor prognosis, 
whereas alpha-fetoprotein cutoffs of 200 ng/mL (.200 ng/mL 
vs ,200 ng/mL HR =1.21; 95% CI: 0.74–1.95; P 0.475) 
(Figure 4B) and 400 ng/mL (.400 ng/mL vs ,400 ng/mL 
HR =1.30; 95% CI: 0.91–1.85; P 0.332) (Figure 4C) were 
not predictive of poor prognosis.
As for etiology, data show that hepatitis B virus (HBV) 
infection (HBV infection vs no HBV infection HR =0.86; 
95% CI: 0.77–0.97; P 0.011) (Figure 5A) was predictive 
of good prognosis, whereas patients with hepatitis C virus 
(HCV) infection vs patients without HCV infection showed 
no statistically significant difference (HR =1.14; 95% CI: 
0.95–1.36; P 0.147) (Figure 5B).
Finally, neutrophil–lymphocyte ratio (NLR) was pre-
dictive of poor prognosis (high vs low HR =1.91; 95% CI: 
1.35–2.70; P,0.0001) (Figure S1D).
recurrence-free survival
The analysis of liver functionality showed that only Child–
Pugh B vs Child–Pugh A was predictive of poor RFS 
(HR =1.24; 95% CI: 1.11–1.40; P,0.0001) (Figure 6A). 
Bilirubin, albumin, prothrombin activity, and portosystemic 
collaterals were not predictive of RFS (Figure S2A–D).
Tumor size was not predictive of RFS when the size of the 
nodule was considered as a continuous variable (HR =1.00; 
95% CI: 0.99–1.01; P 0.465) (Figure 6B). Yet, when the cut-
off was considered, tumor sizes .2 cm vs ,2 cm (HR =1.77; 
95% CI: 1.47–2.12; P,0.0001) (Figure 6C) and .3 cm 
vs ,3 cm (HR =1.31; 95% CI: 1.13–1.53; P,0.0001) 
(Figure 6D) were predictive of poor RFS. When considering 
the number of nodules, the presence of .1 nodule (HR =1.62; 
95% CI: 1.47–1.78; P,0.0001) (Figure 6E) was predictive 
of poor RFS.
Gender was not predictive of RFS (male vs female 
HR =1.05; 95% CI: 0.96–1.15; P 0.243) (Figure S2E), 
whereas an older age (HR =1.01, 95% CI: 1.00–1.01; 
P 0.021) (Figure S2F) was predictive of poor RFS.
Data showed that an alpha-fetoprotein cutoff of 
400 ng/mL (.400 ng/mL vs ,400 ng/mL HR =1.16; 95% CI: 
0.93–1.46; P 0.186) (Figure 6F) was not predictive of RFS.
As for etiology, HBV infection (HBV infection vs no HBV 
infection HR =1.16; 95% CI: 1.03–1.31; P 0.012) (Figure 7A) 
was predictive of poor RFS. The presence of HCV infection 
vs no HCV infection (HR =1.15, 95% CI: 1.04–1.27; P 0.008) 
(Figure 7B) was predictive of poor RFS.
Finally, NLR was not predictive of RFS (high vs low 
HR =1.28; 95% CI: 0.98–1.69; P 0.075).
Publication bias
The funnel plots were evaluated and seemed symmetrical. 
No publication bias was observed and Egger’s tests for 
asymmetry were not significant (P-value=0.851 for OS, 
P=0.806 for RFS and P=0.573).
sensitivity analysis
Sensitivity analyses were performed in order to examine the 
stability of the results (data not shown). The pooled HRs sug-
gest that results were statistically reliable because they were 
not changed substantially omitting 1 study at a time.
Figure 1 Flow diagram of the included and excluded studies.
Abbreviation: rFa, radiof requency ablation.
Electronic search:
2,780 clinical studies
76 full-text articles were
assessed for eligibility
34 studies were included in
the quantitative analysis
2,704 articles were excluded 
15 studies were excluded because
they compared RFA with other
ablating techniques in terms of
efficacy 
15 studies were excluded because
of insufficient data to estimate the
outcomes  
12 studies were excluded because
they compared RFA with surgery in
terms of efficacy 
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Discussion
In this meta-analysis of .10,000 individuals, we evaluated 
what factors are capable of predicting OS and RFS in HCC 
patients treated with RFA. As most studies and meta-analyses 
considered RFA vs surgery, this is the first meta-analysis to 
have evaluated only clinical or laboratory parameters in this 
subset of patients without comparing with surgery.
Our study showed that Child–Pugh B was a significant 
predictor of poor OS (HR =2.32) and RFS (HR =1.24). 
Our data showed that other liver function parameters are 
also highly predictive of poor OS (bilirubin, presence of 
portosystemic circles, prothrombin, and albumin), whereas 
only Child–Pugh B vs Child–Pugh A was predictive of 
poor RFS. The severity of the underlying liver disease may 
also be a risk factor for the development and recurrence 
of HCC, suggesting the importance of the role of the liver 
function in these patients. A recent study by Wei-Yu Kao 
et al12 evaluated ALBI grade and platelet-albumin-bilirubin 
grade as prognostic and predictive indexes in patients treated 
with RFA. The data highlighted a significant difference in 
OS between Child–Pugh A and ALBI grade 1 vs Child–
Pugh A and ALBI grade 1 and 2. This study showed for the 
first time that ALBI grade can better stratify these patients. 
Their results have also been confirmed by Oh Is et al41 and 
CH Lo et al.42 Also, our meta-analysis confirms that ALBI 
grade is currently one of the best indexes for predicting 
Figure 2 Forest plots for overall survival showing child–Pugh (A); bilirubin (B); portosystemic collaterals (C); alBi score (D); prothrombin activity (E); albumin (F).
Abbreviation: alBi, albumin–bilirubin.
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survival in this patient subset. As shown by other works at 
different disease stages,43–45 ALBI grade is better predic-
tive index than Child–Pugh, as the latter is composed of 
5 arbitrary parameters, whereas the former is formed by 
only 2 non-arbitrary parameters (albumin and bilirubin). 
Interestingly, this meta-analysis showed that the presence 
of the portosystemic collateral is a predictive factor of OS. 
As for liver resection, the presence of portal hypertension 
is a well-known predictor for survival, regardless of the 
Child–Pugh class.46,47
Figure 3 Forest plots for overall survival showing the tumor size as a continuous variable (A); cutoff of 2 cm (B); cutoff of 3 cm (C); presence of .1 nodules (D).
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Figure 4 Forest plots for overall survival showing the alpha-fetoprotein with a cutoff of 20 ng/ml (A); cutoff of 200 ng/ml (B); cutoff of 400 ng/ml (C).
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Figure 5 Forest plots for overall survival showing hBV infection (A); hcV infection (B).
Abbreviations: hBV, hepatitis B virus; hcV, hepatitis c virus.
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Figure 6 Forest plots for recurrence-free survival showing child–Pugh (A); tumor size as a continuous variable (B); tumor size with a cutoff of 2 cm (C); tumor size with a 
cutoff of 3 cm (D); presence of .1 nodules (E); alpha-fetoprotein with a cutoff of 400 ng/ml (F).
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Another factor evaluated in this meta-analysis was the pre 
RFA tumor size. The size of the nodules, taken as a continu-
ous variable, was not predictive of either OS or RFS, because 
many studies included in the meta-analysis considered only 
small nodules. Conversely, when we evaluated the size of 
the nodule as a cutoff value, we observed that the maximum 
benefit of RFA was reached when nodules were ,2 cm, con-
firming the literature data48 and supporting the choice of RFA 
as the first treatment option. For tumors .2 cm, other factors 
must also be considered. As for the number of nodules, our 
meta-analysis showed that the presence of multiple nodules is 
a negative prognostic index both in terms of OS (HR =1.59) 
and RFS (HR =1.62): therefore, in most nodular patients, 
especially if operable, RFA is not recommended.
In regard to etiology, our results showed that HBV-positive 
patients have better OS and worse RFS (HR =1.16) when 
treated with RFA. These data, however, are difficult to explain, 
particularly for the contrasting data between OS and RFS. In 
all considered studies, etiology was regarded as presence or 
absence of HBV or HCV infection. Only in 1 study,31 the differ-
ent etiologies were directly compared, highlighting our data as a 
benefit in terms of OS in HBV-positive patients compared with 
HCV-positive patients with a 56% reduction in death risk.
Concerning the predictive role of alpha fetoprotein, our 
meta-analysis revealed that only a cutoff of 20 ng/mL can 
predict OS and RFS outcomes in these patients.
Although NLR might play a role in predicting OS and 
RFS, data are currently limited and cannot be employed in 
normal clinical practice.
Limitations
Among the limitations of our meta-analysis are the low 
number of published studies considered for some subgroup 
analyses by prognostic factor, and the consideration of 
studies only reporting HR and 95% CI, thus potentially 
introducing further bias. Another limitation is that in this is a 
meta-analysis of aggregate patient data and not of individual 
patient data.
Conclusion
Our meta-analysis highlighted that the maximum benefit 
of RFA in terms of OS and RFS is reached when all the 
following features are present: Child–Pugh A, ALBI score 
1, single-nodule tumor sized ,2 cm, and alpha-fetoprotein 
,20 ng/mL. The role of the different etiologies still remains 
to be clarified. These clinical/laboratory data should also 
be used to better stratify patients in future RFA random-
ized trials.
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Supplementary materials
Figure S1 Forest plots for overall survival for male vs female (A), age as continue variable (B), age 65 years (C) and neutrophil–lymphocyte ratio (D).
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Figure S2 Forest plots for recurrence free survival for bilirubin (A), albumin (B), prothrombin activity (C), portosystemic collaterals (D), male vs female (E), and age (F).
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